莱美药业最新筹码趋于集中

Core Viewpoint - Laimei Pharmaceutical reported a decrease in the number of shareholders and a decline in financial performance for the third quarter, indicating potential challenges for the company moving forward [2] Shareholder Information - As of December 10, the number of shareholders for Laimei Pharmaceutical was 31,490, a decrease of 1,813 from the previous period (November 30), representing a month-on-month decline of 5.44% [2] Stock Performance - The closing price of Laimei Pharmaceutical was 4.86 yuan, reflecting an increase of 1.67%. However, since the concentration of shares began, the stock price has cumulatively decreased by 5.63%, with 4 days of increases and 6 days of decreases during this period [2] Financial Performance - For the first three quarters, Laimei Pharmaceutical achieved a total operating revenue of 581 million yuan, a year-on-year decrease of 4.06%. The net profit was -45.9172 million yuan, representing a year-on-year decline of 73.82%. The basic earnings per share were -0.0435 yuan [2]